Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism

Medicinal Research Reviews

Volumn 37, Issue 1, 2017, Pages 3-51

  Vogt, Dominik ^a   Stark, Holger ^b  

^a GOETHE UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

antibodies; ceramide; clinical candidates; fingolimod; S1P; S1P lyase; S1P receptor; sphingosine; sphingosine kinase

Indexed keywords

3 (4 CHLOROPHENYL) N (4 PYRIDINYLMETHYL)ADAMANTANE 1 CARBOXAMIDE; ABC 294735; ABC 747080; CB 5468139; CERALIFIMOD; DEOXYPYRIDOXINE; FINGOLIMOD; GSK 2018682; LYASE INHIBITOR; MONOCLONAL ANTIBODY; MP A 08; OZANIMOD; PF 543; PHOSPHOTRANSFERASE INHIBITOR; PONESIMOD; RB 005; SAFINGOL; SIPONIMOD; SLP 120701; SLP 7111228; SLR 080811; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE; SPISULOSINE; ST 1803; UNCLASSIFIED DRUG; VPC 143144; VPC 143237; VPC 96115; ICOSANOID; LYSOPHOSPHOLIPID; MOLECULAR LIBRARY; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

CELL COMPARTMENTALIZATION; CHRONIC INFLAMMATION; DRUG DESIGN; HUMAN; ICOSANOID METABOLISM; INFLAMMATION; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; MEMBRANE MICRODOMAIN; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY;

ANIMALS; EICOSANOIDS; HUMANS; LYSOPHOSPHOLIPIDS; MEMBRANE MICRODOMAINS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES; SPHINGOSINE;

EID: 84980009964     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21402     Document Type: Review

References (476)

1. Mollinedo F, Gajate C. Lipid rafts as major platforms for signaling regulation in cancer. Adv Biol Regul 2015;57:130–146.
2. Mendez TL, Chatterjee A de, Duarte T, Leon J de, Robles-Martinez L, Das S. Sphingolipids, lipid rafts, and giardial encystation: The show must go on. Curr Trop Med Rep 2015;2(3):136–143.
3. Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM. Role of ceramide in cellular senescence. J Biol Chem 1995;270(51):30701–30708.
4. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 2000;1485(2–3):63–99.
5. Adam D, Heinrich M, Kabelitz D, Schütze S. Ceramide: Does it matter for T cells? Trends Immunol 2002;23(1):1–4.
6. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004;5(8):777–782.
7. Hetz CA, Hunn M, Rojas P, Torres V, Leyton L, Quest, Andrew FG. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: Onset of necrosis is associated with delayed ceramide increase. J Cell Sci 2002;115(Pt 23):4671–4683.
8. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: An overview and current perspectives. Biochim Biophys Acta 2002;1585(2–3):114–125.
9. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9(2):139–150.
10. Bartke N, Hannun YA. Bioactive sphingolipids: Metabolism and function. J Lipid Res 2008;50(Suppl):S91–S96.
11. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010;6(7):489–497.
12. Zhou K, Blom T. Trafficking and functions of bioactive sphingolipids: Lessons from cells and model membranes. Lipid Insights 2015;8(Suppl 1):11–20.
13. Delgado A, Casas J, Llebaria A, Abad JL, Fabriás G. Chemical tools to investigate sphingolipid metabolism and functions. ChemMedChem 2007;2(5):580–606.
14. Olivera A, Allende ML, Proia RL. Shaping the landscape: Metabolic regulation of S1P gradients. Biochim Biophys Acta 2013;1831(1):193–202.
15. Ghasemi R, Dargahi L, Ahmadiani A. Integrated sphingosine-1 phosphate signaling in the central nervous system: From physiological equilibrium to pathological damage. Pharmacol Res 2016;104:156–164.
16. Marin R, Fabelo N, Fernández-Echevarría C, Canerina-Amaro A, Rodríguez-Barreto D, Quinto-Alemany D, Mese-Herrera F, Diaz M. Lipid raft alterations in aged-associated neuropathologies. Curr Alzheimer Res 2016;epub ahead of print.
17. Olson DK, Fröhlich F, Farese RV, Walther TC. Taming the sphinx: Mechanisms of cellular sphingolipid homeostasis. Biochim Biophys Acta 2016;1861(8 Pt B):784–792.
18. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta 1998;1436(1–2):233–243.
19. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: Stress encounters of the lipid kind. J Biol Chem 2002;277(29):25847–25850.
20. Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005;15(6):312–318.
21. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 2006;281(35):25001–25005.
22. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol 1994;72(11–12):471–474.
23. Levade T, Augé N, Veldman RJ, Cuvillier O, Nègre-Salvayre A, Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 2001;89(11):957–968.
24. Levade T, Jaffrézou JP. Signalling sphingomyelinases: Which, where, how and why? Biochim Biophys Acta 1999;1438(1):1–17.
25. Kamil B, Anna F, Anna S, Sławomir P, Halina C. Regulation of sphingomyelin metabolism. Pharmacol Rep 2016;68(3):570–581.
26. 2 acts on cellular membranes to generate ceramide signaling and initiate apoptosis in tracheobronchial epithelial cells. J Cell Sci 1998;111(Pt 21):3209–3220.
27. Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 1997;272(26):16281–16287.
28. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 1998;273(18):11313–11320.
29. Mathias S, Peña LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998;335(Pt 3):465–480.
30. Jenkins GM, Cowart LA, Signorelli P, Pettus BJ, Chalfant CE, Hannun YA. Acute activation of de novo sphingolipid biosynthesis upon heat shock causes an accumulation of ceramide and subsequent dephosphorylation of SR proteins. J Biol Chem 2002;277(45):42572–42578.
31. Siow D, Sunkara M, Morris A, Wattenberg B. Regulation of de novo sphingolipid biosynthesis by the ORMDL proteins and sphingosine kinase-1. Adv Biol Regul 2015;57:42–54.
32. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 1995;82(3):405–414.
33. Schiffmann S, Hartmann D, Fuchs S, Birod K, Ferreiròs N, Schreiber Y, et al. Inhibitors of specific ceramide synthases. Biochimie 2012;94(2):558–565.
34. Jeckel D, Karrenbauer A, Burger KN, van Meer G, Wieland F. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J Cell Biol 1992;117(2):259–267.
35. Yamaji T, Kumagai K, Tomishige N, Hanada K. Two sphingolipid transfer proteins, CERT and FAPP2: Their roles in sphingolipid metabolism. IUBMB Life 2008;60(8):511–518.
36. Bajjalieh SM, Martin TF, Floor E. Synaptic vesicle ceramide kinase. A calcium-stimulated lipid kinase that co-purifies with brain synaptic vesicles. J Biol Chem 1989;264(24):14354–14360.
37. Kolesnick RN, Hemer MR. Characterization of a ceramide kinase activity from human leukemia (HL-60) cells. Separation from diacylglycerol kinase activity. J Biol Chem 1990;265(31):18803–18808.
38. Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: Expanding roles in cell signaling. J Cell Sci 2005;118(Pt 20):4605–4612.
39. Arana L, Gangoiti P, Ouro A, Trueba M, Gómez-Muñoz A. Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis 2010;9:15.
40. Bornancin F. Ceramide kinase: The first decade. Cell Signal 2011;23(6):999–1008.
41. Simanshu DK, Kamlekar RK, Wijesinghe DS, Zou X, Zhai X, Mishra SK, et al. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature 2013;500(7463):463–467.
42. Stoffel W, Heimann G, Hellenbroich B. Sphingosine kinase in blood platelets. Hoppe-Seyler's Z Physiol Chem 1973;354(5):562–566.
43. Brindley DN, Waggoner DW. Mammalian lipid phosphate phosphohydrolases. J Biol Chem 1998;273(38):24281–24284.
44. Aguilar A, Saba JD. Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 2012;52(1):17–30.
45. Van Veldhoven, PP, Gijsbers S, Mannaerts GP, Vermeesch JR, Brys V. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). Biochim Biophys Acta 2000;1487(2–3):128–134.
46. Kim RH, Takabe K, Milstien S, Spiegel S. Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 2009;1791(7):692–696.
47. Liu X, Zhang Q, Yi G. Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem 2012;363(1–2):21–33.
48. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103(44):16394–16399.
49. Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M, et al. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J Neurochem 2007;103(6):2610–2619.
50. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev 2008;60(2):181–195.
51. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 2010;285(14):10477–10486.
52. Nishi T, Kobayashi N, Hisano Y, Kawahara A, Yamaguchi A. Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 2014;1841(5):759–765.
53. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 2012;122(4):1416–1426.
54. Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, et al. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J 2013;27(3):1001–1011.
55. Donoviel MS, Hait NC, Ramachandran S, Maceyka M, Takabe K, Milstien S, et al. Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases. FASEB J 2015;29(12):5018–5028.
56. Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, Hannun YA, et al. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: Modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem 2001;276(38):35258–35264.
57. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000;352(Pt 3):809–815.
58. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011;108(23):9613–9618.
59. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem 1997;121(5):969–973.
60. Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21(4):1202–1209.
61. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316(5822):295–298.
62. Gómez-Muñoz A, Waggoner DW, O'Brien L, Brindley DN. Interaction of ceramides, sphingosine, and sphingosine 1-phosphate in regulating DNA synthesis and phospholipase D activity. J Biol Chem 1995;270(44):26318–26325.
63. Pyne S, Chapman J, Steele L, Pyne NJ. Sphingomyelin-derived lipids differentially regulate the extracellular signal-regulated kinase 2 (ERK-2) and c-Jun N-terminal kinase (JNK) signal cascades in airway smooth muscle. Eur J Biochem 1996;237(3):819–826.
64. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381(6585):800–803.
65. Gomez-Muñoz A, Presa N, Gomez-Larrauri A, Rivera I, Trueba M, Ordoñez M. Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res 2016;61:51–62.
66. Jin L, Liu W, Tian M, Fan J, Shi Y. The SphKs/S1P/S1PR1 axis in immunity and cancer: More ore to be mined. World J Surg Oncol 2016;14(1):131.
67. Maceyka M, Milstien S, Spiegel S. Sphingosine-1-phosphate: The Swiss army knife of sphingolipid signaling. J Lipid Res 2009;50(Suppl):S272–S276.
68. Van Brocklyn JR, Williams JB. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 2012;163(1):26–36.
69. Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Prog Lipid Res 2016;62:93–106.
70. El Alwani M, Wu BX, Obeid LM, Hannun YA. Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacol Ther 2006;112(1):171–183.
71. Xia P, Wang L, Moretti PAB, Albanese N, Chai F, Pitson SM, et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem 2002;277(10):7996–8003.
72. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010;465(7301):1084–1088.
73. Blom T, Bergelin N, Meinander A, Löf C, Slotte JP, Eriksson JE, et al. An autocrine sphingosine-1-phosphate signaling loop enhances NF-κB-activation and survival. BMC Cell Biol 2010;11(1):45.
74. Blackwell K, Zhang L, Workman LM, Ting AT, Iwai K, Habelhah H. Two coordinated mechanisms underlie tumor necrosis factor alpha-induced immediate and delayed IκB kinase activation. Mol Cell Biol 2013;33(10):1901–1915.
75. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 2003;17(11):1411–1421.
76. Nakamura H, Murayama T. Role of sphingolipids in arachidonic acid metabolism. J Pharmacol Sci 2014;124(3):307–312.
77. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006;20(2):386–388.
78. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009;23(2):405–414.
79. Schmelz EM. Sphingolipids in the chemoprevention of colon cancer. Front Biosci 2004;9:2632–2639.
80. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2. Oncology 2005;69(Suppl 1):28–32.
81. Suh JH, Saba JD. Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: The fat's in the fire. Transl Cancer Res 2015;4(5):469–483.
82. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15(14):2742–2744.
83. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: From prevention to therapy. Br J Cancer 2003;88(6):803–807.
84. Schiffmann S, Sandner J, Schmidt R, Birod K, Wobst I, Schmidt H, et al. The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res 2009;50(1):32–40.
85. Clark JD, Schievella AR, Nalefski EA, Lin LL. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 1995;12(2–3):83–117.
86. Glover S, de Carvalho, M S, Bayburt T, Jonas M, Chi E, Leslie CC, et al. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem 1995;270(25):15359–15367.
87. Schievella AR, Regier MK, Smith WL, Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 1995;270(51):30749–30754.
88. Scott KF, Bryant KJ, Bidgood MJ. Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation. J Leukoc Biol 1999;66(4):535–541.
89. Chen L, Woszczek G, Nagineni S, Logun C, Shelhamer JH. Cytosolic phospholipase A2 activation induced by S1P is mediated by the S1P3 receptor in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008;295(2):L326–L335.
90. Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D, Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: Function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal 2005;17(10):1203–1217.
91. Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, et al. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: Regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum 2006;54(3):742–753.
92. Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 2004;279(12):11320–11326.
93. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, et al. The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol 2005;68(2):330–335.
94. Baumruker T, Bornancin F, Billich A. The role of sphingosine and ceramide kinases in inflammatory responses. Immunol Lett 2005;96(2):175–185.
95. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9(2):162–176.
96. Lill A, Stark H. Sphingolipide - Fettähnliche Botenstoffe mit großer Wirkung. PZ Prisma 2012;19(1):17–27.
97. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012;22(1):50–60.
98. Pyne NJ, McNaughton M, Boomkamp S, MacRitchie N, Evangelisti C, Martelli AM, et al. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv Biol Regul 2016;60:151–159.
99. Knapp M. Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 2011;62(6):601–607.
100. Wang F, Van Brocklyn J R, Hobson JP, Movafagh S, Zukowska-Grojec Z, Milstien S, et al. Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis. J Biol Chem 1999;274(50):35343–35350.
101. Swan DJ, Kirby JA, Ali S. Vascular biology: The role of sphingosine 1-phosphate in both the resting state and inflammation. J Cell Mol Med 2010;14(9):2211–2222.
102. Sanchez T. Sphingosine-1-phosphate signaling in endothelial disorders. Curr Atheroscler Rep 2016;18(6):31.
103. Chi H. Sphingosine-1-phosphate and immune regulation: Trafficking and beyond. Trends Pharmacol Sci 2011;32(1):16–24.
104. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011;11(6):403–415.
105. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009;458(7237):524–528.
106. Obinata H, Hla T. Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol 2012;34(1):73–91.
107. Patti GJ, Yanes O, Shriver LP, Courade J, Tautenhahn R, Manchester M, et al. Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin. Nat Chem Biol 2012;8(3):232–234.
108. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: Dual messenger functions. FEBS Lett 2002;531(1):54–57.
109. Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MBA. Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence. Annu Rev Biochem 2013;82:637–662.
110. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003;47(5):401–407.
111. Huwiler A, Pfeilschifter J. Lipids as targets for novel anti-inflammatory therapies. Pharmacol Ther 2009;124(1):96–112.
112. Nixon GF. Sphingolipids in inflammation: Pathological implications and potential therapeutic targets. Br J Pharmacol 2009;158(4):982–993.
113. Bigaud M, Guerini D, Billich A, Bassilana F, Brinkmann V. Second generation S1P pathway modulators: Research strategies and clinical developments. Biochim Biophys Acta 2014;1841(5):745–758.
114. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: New therapies and opportunities. F1000Prime Rep 2014;6:109.
115. Imeri F, Fallegger D, Zivkovic A, Schwalm S, Enzmann G, Blankenbach K, et al. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice. Neuropharmacology 2014;85:314–327.
116. Candido K, Sioufi H, Bandyopadhyay M, Dasgupta S. Therapeutic impact of sphingosine 1-phosphate receptor signaling in multiple sclerosis. Mini Rev Med Chem 2016;16(7):547–554.
117. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008;49:413–440.
118. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10(7):489–503.
119. Patmanathan SN, Yap LF, Murray PG, Paterson IC. The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod. J Cell Mol Med 2015;19(10):2329–2340.
120. Stevenson CE, Takabe K, Nagahashi M, Milstien S, Spiegel S. Targeting sphingosine-1-phosphate in hematologic malignancies. Anticancer Agents Med Chem 2011;11(9):794–798.
121. Ryan JJ, Spiegel S. The role of sphingosine-1-phosphate and its receptors in asthma. Drug News Perspect 2008;21(2):89–96.
122. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis 2011;5(5):325–344.
123. Ono JG, Worgall TS, Worgall S. Airway reactivity and sphingolipids-implications for childhood asthma. Mol Cell Pediatr 2015;2(1):13.
124. Petrache I, Berdyshev EV. Ceramide signaling and metabolism in pathophysiological states of the lung. Annu Rev Physiol 2016;78:463–480.
125. Li Y, Li R, Samuel SB, Cueto R, Li X, Wang H, et al. Lysophospholipids and their G protein-coupled receptors in atherosclerosis. Front Biosci (Landmark Ed) 2016;21(1):70–88.
126. D'Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochim Biophys Acta 2016;epub ahead of print.
127. Kurek K, Łukaszuk B, Piotrowska DM, Wiesiołek P, Chabowska AM, Żendzian-Piotrowska M. Metabolism, physiological role, and clinical implications of sphingolipids in gastrointestinal tract. BioMed Res Int 2013;9(20):1–10.
128. Abdel Hadi L, Di Vito C, Riboni L. Fostering inflammatory bowel disease: Sphingolipid strategies to join forces. Mediators Inflamm 2016;2016:3827684.
129. Frej C, Linder A, Happonen KE, Taylor FB, Lupu F, Dahlbäck B. Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons. J Cell Mol Med 2016;20(6):1170–1181.
130. Lai W, Irwan AW, Goh HH, Howe HS, Yu DT, Valle-Oñate R, et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol 2008;181(11):8010–8017.
131. Hu P, Chen Y, Cai P, Jiang L, Wu L. Sphingosine-1-phosphate: A potential therapeutic target for rheumatoid arthritis. Mol Biol Rep 2011;38(6):4225–4230.
132. Cowart LA. Sphingolipids: Players in the pathology of metabolic disease. Trends Endocrinol Metab 2009;20(1):34–42.
133. Choi S, Snider AJ. Sphingolipids in high fat diet and obesity-related diseases. Mediators Inflamm 2015;2015:520618.
134. Kolesnick R, Hannun YA. Ceramide and apoptosis. Trends Biochem Sci 1999;24(6):224–225.
135. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4(8):604–616.
136. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206(2):169–180.
137. Ueda N. Ceramide-induced apoptosis in renal tubular cells: A role of mitochondria and sphingosine-1-phoshate. Int J Mol Sci 2015;16(3):5076–5124.
138. Spiegel S, Milstien S. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4(5):397–407.
139. Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004;5(4):375–382.
140. Modrak DE. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006;5(2):200–208.
141. Pyne S, Bittman R, Pyne NJ. Sphingosine kinase inhibitors and cancer: Seeking the golden sword of Hercules. Cancer Res 2011;71(21):6576–6582.
142. Gómez-Muñoz A, Kong JY, Parhar K, Wang SW, Gangoiti P, González M, et al. Ceramide-1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. FEBS Lett 2005;579(17):3744–3750.
143. Giussani P, Tringali C, Riboni L, Viani P, Venerando B. Sphingolipids: Key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Med Sci 2014;15(3):4356–4392.
144. Perry DK, Kolesnick RN. Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 2003;115:345–354.
145. Huwiler A, Zangemeister-Wittke U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 2007;63(2):150–159.
146. Leong WI, Saba JD. S1P metabolism in cancer and other pathological conditions. Biochimie 2010;92(6):716–723.
147. Furuya H, Shimizu Y, Kawamori T. Sphingolipids in cancer. Cancer Metastasis Rev 2011;30(3–4):567–576.
148. Yester JW, Tizazu E, Harikumar KB, Kordula T. Extracellular and intracellular sphingosine-1-phosphate in cancer. Cancer Metastasis Rev 2011;30(3-4):577–597.
149. Delgado A, Fabrias G, Bedia C, Casas J, Abad JL. Sphingolipid modulation: A strategy for cancer therapy. Anticancer Agents Med Chem 2012;12(4):285–302.
150. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63(18):5962–5969.
151. Van Brocklyn, JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005;64(8):695–705.
152. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758(12):2016–2026.
153. Li J, Guan H, Gong L, Song L, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008;14(21):6996–7003.
154. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008;9(8):662–673.
155. Vadas M, Xia P, McCaughan G, Gamble J. The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction? Biochim Biophys Acta 2008;1781(9):442–447.
156. Li W, Yu C, Xia J, Zhang L, Weng G, Zheng H, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009;15(4):1393–1399.
157. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005;53(9):1159–1166.
158. Ruckhäberle E, Rody A, Engels K, Gaetje R, Minckwitz G von, Schiffmann S, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008;112(1):41–52.
159. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, et al. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 2015;49(5):948–954.
160. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000;10(23):1527–1530.
161. Pyne S, Pyne NJ. Translational aspects of sphingosine 1-phosphate biology. Trends Mol Med 2011;17(8):463–472.
162. Pyne S, Edwards J, Ohotski J, Pyne NJ. Sphingosine 1-phosphate receptors and sphingosine kinase 1: Novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol 2012;2:168.
163. Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 1998;63(9):1057–1060.
164. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol 2010;30(15):3827–3841.
165. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010;177(5):2205–2215.
166. Maczis M, Milstien S, Spiegel S. Sphingosine-1-phosphate and estrogen signaling in breast cancer. Adv Biol Regul 2016;60:160–165.
167. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim T, Murate T, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 2006;342(4):1284–1290.
168. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008;7(7):1836–1845.
169. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012;72(3):726–735.
170. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012;4(8):761–775.
171. Sordillo LA, Sordillo PP, Helson L. Sphingosine kinase inhibitors as maintenance therapy of glioblastoma after ceramide-induced response. Anticancer Res 2016;36(5):2085–2095.
172. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65(24):11667–11675.
173. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009;8(4):809–820.
174. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007;282(15):10922–10934.
175. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008;22(5):971–979.
176. Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, et al. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: Relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J Hematol 2008;87(3):266–275.
177. Sietsma H, Veldman RJ, Kok JW. The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181(3):153–162.
178. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996;271(32):19530–19536.
179. De Rosa, MF, Sillence D, Ackerley C, Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J Biol Chem 2004;279(9):7867–7876.
180. Chen B, Roy SG, McMonigle RJ, Keebaugh A, McCracken AN, Selwan E, et al. Azacyclic FTY720 analogues that limit nutrient transporter expression but lack S1P receptor activity and negative chronotropic effects offer a novel and effective strategy to kill cancer cells in vivo. ACS Chem Biol 2016;11(2):409–414.
181. Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014;57(13):5509–5524.
182. Andrieu-Abadie N, Gouazé V, Salvayre R, Levade T. Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radic Biol Med 2001;31(6):717–728.
183. Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001;4(6):368–377.
184. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism—A strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93(5):347–357.
185. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol 2010;688:185–205.
186. Burns TA, Luberto C. Sphingolipid metabolism and leukemia: A potential for novel therapeutic approaches. Anticancer Agents Med Chem 2011;11(9):863–881.
187. Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y. Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem 2013;20(1):108–122.
188. Litvak DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy. J Gastrointest Surg 2003;7(1):140–148.
189. Chauvier D, Morjani H, Manfait M. Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells. Int J Oncol 2002;20(4):855–863.
190. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 2000;275(12):9078–9084.
191. Biswal SS, Datta K, Acquaah-Mensah GK, Kehrer JP. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology 2000;154(1–3):45–53.
192. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003;111(2 Suppl):S460–S475.
193. Roviezzo F, Del Galdo F, Abbate G, Bucci M, D'Agostino B, Antunes E, et al. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci USA 2004;101(30):11170–11175.
194. Deigner HP, Gulbins E, Claus RA. Sphingolipid metabolism in systemic inflammation. In: Vincent J, Ed. Intensive Care Medicine. Berlin, Heidelberg: Springer; 2007. p 249–266.
195. Gräler MH. Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cell Physiol Biochem 2010;26(1):79–86.
196. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014;510(7503):58–67.
197. Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K. Sphingosine-1-phosphate signaling in immune cells and inflammation: Roles and therapeutic potential. Mediators Inflamm 2016;2016:8606878.
198. Kee TH, Vit P, Melendez AJ. Sphingosine kinase signalling in immune cells. Clin Exp Pharmacol Physiol 2005;32(3):153–161.
199. Melendez AJ. Sphingosine kinase signalling in immune cells: Potential as novel therapeutic targets. Biochim Biophys Acta 2008;1784(1):66–75.
200. Schwab SR, Cyster JG. Finding a way out: Lymphocyte egress from lymphoid organs. Nat Immunol 2007;8(12):1295–1301.
201. Arnon TI, Horton RM, Grigorova IL, Cyster JG. Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress. Nature 2013;493(7434):684–688.
202. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 2009;206(11):2469–2481.
203. Cinamon G, Zachariah MA, Lam OM, Foss FW, Cyster JG. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008;9(1):54–62.
204. Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, et al. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest 2010;120(11):3979–3995.
205. Allende ML, Bektas M, Lee BG, Bonifacino E, Kang J, Tuymetova G, et al. Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 2011;286(9):7348–7358.
206. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004;199(7):959–970.
207. Thangada S, Khanna KM, Blaho VA, Oo ML, Im D, Guo C, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 2010;207(7):1475–1483.
208. Rathinasamy A, Czeloth N, Pabst O, Förster R, Bernhardt G. The origin and maturity of dendritic cells determine the pattern of sphingosine 1-phosphate receptors expressed and required for efficient migration. J Immunol 2010;185(7):4072–4081.
209. König K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, Kahl P, et al. Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration. J Immunol 2010;185(3):1466–1475.
210. Melendez AJ. Allergy therapy: The therapeutic potential of targeting sphingosine kinase signalling in mast cells. Eur J Immunol 2008;38(11):2969–2974.
211. Oskeritzian CA, Price MM, Hait NC, Kapitonov D, Falanga YT, Morales JK, et al. Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. J Exp Med 2010;207(3):465–474.
212. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006;117(6):1214-1225.
213. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood 2008;111(8):4193–4200.
214. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012;106(1):9–14.
215. Oskeritzian CA, Milstien S, Spiegel S. Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacol Ther 2007;115(3):390–399.
216. Olivera A, Urtz N, Mizugishi K, Yamashita Y, Gilfillan AM, Furumoto Y, et al. IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. J Biol Chem 2006;281(5):2515–2525.
217. Urtz N, Olivera A, Bofill-Cardona E, Csonga R, Billich A, Mechtcheriakova D, et al. Early activation of sphingosine kinase in mast cells and recruitment to FcepsilonRI are mediated by its interaction with Lyn kinase. Mol Cell Biol 2004;24(19):8765–8777.
218. Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM, et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 2003;171(11):6206–6214.
219. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9(11):883–897.
220. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012;30:69–94.
221. Halmer R, Walter S, Faβbender K. Sphingolipids: Important players in multiple sclerosis. Cell Physiol Biochem 2014;34(1):111–118.
222. Ghidoni R, Caretti A, Signorelli P. Role of sphingolipids in the pathobiology of lung inflammation. Mediators Inflamm 2015;2015:487508.
223. Paulenda T, Draber P. The role of ORMDL proteins, guardians of cellular sphingolipids, in asthma. Allergy 2016;71(7):918–930.
224. Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G. Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 2006;1758(12):1957–1977.
225. Nussbaumer P. Medicinal chemistry aspects of drug targets in sphingolipid metabolism. ChemMedChem 2008;3(4):543–551.
226. Lynch KR, Macdonald TL. Sphingosine 1-phosphate chemical biology. Biochim Biophys Acta 2008;1781(9):508–512.
227. Sabbadini RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 2011;162(6):1225–1238.
228. Olivera A, Spiegel S. Sphingosine kinase: A mediator of vital cellular functions. Prostaglandins Other Lipid Mediat 2001;64(1–4):123–134.
229. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: Biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006;39(2):113–131.
230. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000;275(26):19513–19520.
231. Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L. Human sphingosine kinase: Molecular cloning, functional characterization and tissue distribution. Gene 2000;251(1):19–26.
232. Kihara A, Anada Y, Igarashi Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. J Biol Chem 2006;281(7):4532–4539.
233. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006;107(4):1454–1458.
234. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993;365(6446):557–560.
235. Rius RA, Edsall LC, Spiegel S. Activation of sphingosine kinase in pheochromocytoma PC12 neuronal cells in response to trophic factors. FEBS Lett 1997;417(2):173–176.
236. Kleuser B, Cuvillier O, Spiegel S. 1Alpha,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res 1998;58(9):1817–1824.
237. Meyer zu Heringdorf, D, Lass H, Kuchar I, Alemany R, Guo Y, Schmidt M, et al. Role of sphingosine kinase in Ca(2+) signalling by epidermal growth factor receptor. FEBS Lett 1999;461(3):217–222.
238. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, et al. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 2001;291(5509):1800–1803.
239. Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 2002;22(22):7758–7768.
240. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22(22):3361–3370.
241. Döll F, Pfeilschifter J, Huwiler A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim Biophys Acta 2005;1738(1–3):72–81.
242. Huwiler A, Döll F, Ren S, Klawitter S, Greening A, Römer I, et al. Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. Biochim Biophys Acta 2006;1761(3):367–376.
243. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: The role of sphingosine kinase-1. J Cell Biol 2006;173(2):301–310.
244. Jeng Y, Suarez VR, Izban MG, Wang H, Soloff MS. Progesterone-induced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences. Am J Physiol Endocrinol Metab 2007;292(4):E1110–E1121.
245. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S, et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol 2007;37(4):395–404.
246. Pyne S, Lee SC, Long J, Pyne NJ. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal 2009;21(1):14–21.
247. Rábano M, Peña A, Brizuela L, Marino A, Macarulla JM, Trueba M, et al. Sphingosine-1-phosphate stimulates cortisol secretion. FEBS Lett 2003;535(1–3):101–105.
248. Brizuela L, Rábano M, Peña A, Gangoiti P, Macarulla JM, Trueba M, et al. Sphingosine 1-phosphate: A novel stimulator of aldosterone secretion. J Lipid Res 2006;47(6):1238–1249.
249. Brizuela L, Rábano M, Gangoiti P, Narbona N, Macarulla JM, Trueba M, et al. Sphingosine-1-phosphate stimulates aldosterone secretion through a mechanism involving the PI3K/PKB and MEK/ERK 1/2 pathways. J Lipid Res 2007;48(10):2264–2274.
250. Melendez A, Floto RA, Gillooly DJ, Harnett MM, Allen JM. FcgammaRI coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. J Biol Chem 1998;273(16):9393–9402.
251. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem 2002;277(38):35257–35262.
252. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011;36(2):97–107.
253. Pitson SM, Moretti, PAB, Zebol JR, Lynn HE, Xia P, Vadas MA, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003;22(20):5491–5500.
254. Pitson SM, Xia P, Leclercq TM, Moretti, PAB, Zebol JR, Lynn HE, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005;201(1):49–54.
255. Stahelin RV, Hwang JH, Kim J, Park Z, Johnson KR, Obeid LM, et al. The mechanism of membrane targeting of human sphingosine kinase 1. J Biol Chem 2005;280(52):43030–43038.
256. Ancellin N, Colmont C, Su J, Li Q, Mittereder N, Chae S, et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002;277(8):6667–6675.
257. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 2004;92(5):882–899.
258. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee Y, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 2006;397(3):461–471.
259. Ren S, Xin C, Pfeilschifter J, Huwiler A. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): Induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol Biochem 2010;26(1):97–104.
260. Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010;285(50):38841–38852.
261. Wang Z, Min X, Xiao S, Johnstone S, Romanow W, Meininger D, et al. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure 2013;21(5):798–809.
262. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998;273(37):23722–23728.
263. Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem 1998;273(20):12576–12583.
264. Pitson SM, D'andrea RJ, Vandeleur L, Moretti PA, Xia P, Gamble JR, et al. Human sphingosine kinase: Purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem J 2000;350(Pt 2):429–441.
265. Wang J, Knapp S, Pyne NJ, Pyne S, Elkins JM. Crystal structure of sphingosine kinase 1 with PF-543. ACS Med Chem Lett 2014;5(12):1329–1333.
266. Yokota S, Taniguchi Y, Kihara A, Mitsutake S, Igarashi Y. Asp177 in C4 domain of mouse sphingosine kinase 1a is important for the sphingosine recognition. FEBS Lett 2004;578(1–2):106–110.
267. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005;280(44):37118–37129.
268. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007;374(5–6):413–428.
269. Don AS, Rosen H. A lipid binding domain in sphingosine kinase 2. Biochem Biophys Res Commun 2009;380(1):87–92.
270. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003;278(47):46832–46839.
271. Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Jahangeer S, et al. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem 2007;282(37):27493–27502.
272. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 2009;10(1):32–42.
273. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325(5945):1254–1257.
274. Yoshimoto T, Furuhata M, Kamiya S, Hisada M, Miyaji H, Magami Y, et al. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. J Immunol 2003;171(3):1352–1359.
275. Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem 2007;282(16):12058–12065.
276. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003;278(41):40330–40336.
277. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007;67(21):10466–10474.
278. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004;279(50):52487–52492.
279. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005;25(24):11113–11121.
280. Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010;10(4):354–367.
281. Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 2013;280(21):5317–5336.
282. Orr G, K Alexa, Obeid LM. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: Review of sphingosine kinase inhibitors. Biochim Biophys Acta 2013;1831(1):157–166.
283. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, et al. Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 2010;6(10):1603–1624.
284. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y. N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 1996;35(2):626–633.
285. Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S, et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996;66(3):358–366.
286. 2+ concentration in human cancer cells. Int J Mol Med 2014;33(1):17–24.
287. Igarashi Y, Hakomori S, Toyokuni T, Dean B, Fujita S, Sugimoto M, et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 1989;28(17):6796–6800.
288. Sugiura M, Kono K, Liu H, Shimizugawa T, Minekura H, Spiegel S, et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J Biol Chem 2002;277(26):23294–23300.
289. Buehrer BM, Bell RM. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J Biol Chem 1992;267(5):3154–3159.
290. Coward J, Ambrosini G, Musi E, Truman J, Haimovitz-Friedman A, Allegood JC, et al. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009;5(2):184–193.
291. Dickson MA, Carvajal RD, Merrill AH, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of Safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 2011;17(8):2484–2492.
292. Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, et al. Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer 2015;15(1):762.
293. Kim J, Kim Y, Inagaki Y, Hwang Y, Mitsutake S, Ryu Y, et al. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg Med Chem 2005;13(10):3475–3485.
294. Hara-Yokoyama M, Terasawa K, Ichinose S, Watanabe A, Podyma-Inoue KA, Akiyoshi K, et al. Sphingosine kinase 2 inhibitor SG-12 induces apoptosis via phosphorylation by sphingosine kinase 2. Bioorg Med Chem Lett 2013;23(7):2220–2224.
295. Jonghe S de, van Overmeire I, Poulton S, Hendrix C, Busson R, van Calenbergh S, et al. Structure-activity relationship of short-chain sphingoid bases as inhibitors of sphingosine kinase. Bioorg Med Chem Lett 1999;9(21):3175–3180.
296. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008;112(4):1382–1391.
297. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009;69(17):6915–6923.
298. Byun H, Pyne S, MacRitchie N, Pyne NJ, Bittman R. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Med Chem Comm 2013;4(10):1394-1399.
299. Wong L, Tan Sheryl SL, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem 2009;52(12):3618–3626.
300. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010;22(10):1536–1542.
301. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011;286(21):18633–18640.
302. Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal 2011;23(10):1590–1595.
303. Baek DJ, MacRitchie N, Pyne NJ, Pyne S, Bittman R. Synthesis of selective inhibitors of sphingosine kinase 1. Chem Commun 2013;49(21):2136-2138.
304. Baek DJ, MacRitchie N, Anthony NG, Mackay SP, Pyne S, Pyne NJ, et al. Structure–activity relationships and molecular modeling of sphingosine kinase inhibitors. J Med Chem 2013;56(22):9310–9327.
305. Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One 2013;8(2):e56471.
306. Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, et al. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 2010;53(7):2766–2778.
307. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, et al. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 2011;54(10):3524–3548.
308. Houck JD, Dawson TK, Kennedy AJ, Kharel Y, Naimon ND, Field SD, et al. Structural requirements and docking analysis of amidine-based sphingosine kinase 1 inhibitors containing oxadiazoles. ACS Med Chem Lett 2016;7(5):487–492.
309. Kharel Y, Mathews TP, Gellett AM, Tomsig JL, Kennedy PC, Moyer ML, et al. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J 2011;440(3):345–353.
310. Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, et al. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 2012;447(1):149–157.
311. Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: Discovery of SphK1- and SphK2-selective inhibitors. J Med Chem 2015;58(4):1879–1899.
312. Raje MR, Knott K, Kharel Y, Bissel P, Lynch KR, Santos WL. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med Chem 2012;20(1):183–194.
313. Knott K, Kharel Y, Raje MR, Lynch KR, Santos WL. Effect of alkyl chain length on sphingosine kinase 2 selectivity. Bioorg Med Chem Lett 2012;22(22):6817–6820.
314. Kono K, Tanaka M, Ogita T, Kohama T. Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot 2000;53(8):759–764.
315. Kono K, Tanaka M, Ogita T, Hosoya T, Kohama T. F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot 2000;53(5):459–466.
316. Kono K, Sugiura M, Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J Antibiot 2002;55(1):99–103.
317. Kono K, Tanaka M, Ono Y, Hosoya T, Ogita T, Kohama T. S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus. J Antibiot 2001;54(5):415–420.
318. Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006;118(10):2412–2420.
319. Kang JS, Yoon YD, Han MH, Han S, Lee K, Lee KH, et al. Glabridin suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking sphingosine kinase pathway: Implications of Akt, extracellular signal-regulated kinase, and nuclear factor-kappaB/Rel signaling pathways. Mol Pharmacol 2006;69(3):941–949.
320. Lim KG, Gray AI, Pyne S, Pyne NJ. Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol 2012;166(5):1605–1616.
321. Kuroda I, Musman M, Ohtani II, Ichiba T, Tanaka J, Gravalos DG, et al. Pachastrissamine, a cytotoxic anhydrophytosphingosine from a marine sponge, Pachastrissa sp. J Nat Prod 2002;65(10):1505–1506.
322. Yoshimitsu Y, Oishi S, Miyagaki J, Inuki S, Ohno H, Fujii N. Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C. Bioorg Med Chem 2011;19(18):5402–5408.
323. Salma Y, Lafont E, Therville N, Carpentier S, Bonnafé M, Levade T, et al. The natural marine anhydrophytosphingosine, jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochem Pharmacol 2009;78(5):477–485.
324. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318(2):596–603.
325. Leroux ME, Auzenne E, Evans R, Hail N, Spohn W, Ghosh SC, et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 2007;67(15):1699–1717.
326. Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol 2009;64(5):1053–1058.
327. Song L, Xiong H, Li J, Liao W, Wang L, Wu J, et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res 2011;17(7):1839–1849.
328. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008;53(4):997–1012.
329. Nishiuma T, Nishimura Y, Okada T, Kuramoto E, Kotani Y, Jahangeer S, et al. Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol 2008;294(6):L1085-1093.
330. Chiba Y, Takeuchi H, Sakai H, Misawa M. SKI-II, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice. J Pharmacol Sci 2010;114(3):304–310.
331. Ricci C, Onida F, Servida F, Radaelli F, Saporiti G, Todoerti K, et al. In vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br J Haematol 2009;144(3):350–357.
332. Yang L, Weng W, Sun Z, Fu X, Ma J, Zhuang W. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochem Biophys Res Commun 2015;460(4):903–908.
333. Liu Y, Zhu Z, Cai H, Liu Q, Zhou H, Zhu Z. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol Lett 2014;8(1):367–373.
334. Li P, Wu J, Zheng J, Pei D. A sphingosine kinase-1 inhibitor, SKI-II, induces growth inhibition and apoptosis in human gastric cancer cells. Asian Pac J Cancer Prev 2014;15(23):10381–10385.
335. Rödl CB, Vogt D, Kretschmer, SBM, Ihlefeld K, Barzen S, Brüggerhoff A, et al. Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism. Eur J Med Chem 2014;84:302–311.
336. Cingolani F, Casasampere M, Sanllehí P, Casas J, Bujons J, Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res 2014;55(8):1711–1720.
337. McNaughton M, Pitman M, Pitson SM, Pyne NJ, Pyne S. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget 2016;7(13):16663–16675.
338. Tani K, Tabuchi K, Hara A. Hair cell loss induced by sphingosine and a sphingosine kinase inhibitor in the rat cochlea. Neurotox Res 2016;29(1):35–46.
339. Potì F, Ceglarek U, Burkhardt R, Simoni M, Nofer J. SKI-II—A sphingosine kinase 1 inhibitor–exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis 2015;240(1):212–215.
340. Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 2010;20(24):7498–7502.
341. Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung S, et al. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines. J Pharmacol Exp Ther 2015;352(3):494–508.
342. Sharma AK, Sk UH, Gimbor MA, Hengst JA, Wang X, Yun J, et al. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur J Med Chem 2010;45(9):4149–4156.
343. Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, Wanska M, et al. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg Med Chem Lett 2013;23(16):4608–4616.
344. Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, et al. Sphingosine kinase activity is not required for tumor cell viability. PLoS One 2013;8(7):e68328.
345. Wang X, Sun C, Fang L, Yin D. Discovery of novel sphingosine kinase 1 inhibitors via structure-based hierarchical virtual screening. Med Chem Commun 2015;6(3):413–417.
346. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333(1):129–139.
347. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011;11(7):678–689.
348. Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal—A breast cancer. Exp Biol Med (Maywood) 2012;237(7):832–844.
349. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010;333(2):454–464.
350. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011;29(6):1132–1142.
351. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011;11(5):524–534.
352. Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 2012;7(9):e44543.
353. Thomas MB, Britten CD, Garrett-Mayer E, Chin SH, Bentz TA, Brisendine A, et al. Abstract C62: Phase I trial of ABC294640, a first-in-class sphingosine kinase-2 inhibitor. Mol Cancer Ther 2014;12(11 Suppl):C62.
354. Snider AJ, Ruiz P, Obeid LM, Oates JC. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One 2013;8(1):e53521.
355. Fitzpatrick LR, Green C, Maines LW, Smith CD. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2. Pharmacology 2011;87(3–4):135–143.
356. Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology 2011;19(2):75–87.
357. Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: Implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 2006;47(11):5022–5031.
358. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, et al. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther 2015;14(12):2744–2752.
359. Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology 2010;18(2):73–85.
360. Chumanevich AA, Poudyal D, Cui X, Davis T, Wood PA, Smith CD, et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010;31(10):1787–1793.
361. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010;151(11):5124–5135.
362. Baker DA, Barth J, Chang R, Obeid LM, Gilkeson GS. Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-induced arthritis. J Immunol 2010;185(4):2570–2579.
363. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012;444(1):79–88.
364. Zhang Y, Berka V, Song A, Sun K, Wang W, Zhang W, et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest 2014;124(6):2750–2761.
365. MacRitchie N, Volpert G, Al Washih M, Watson DG, Futerman AH, Kennedy S, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal 2016;28(8):946–955.
366. Xiang Y, Asmussen G, Booker M, Hirth B, Kane JL, Liao J, et al. Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett 2009;19(21):6119–6121.
367. Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, et al. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett 2010;20(15):4550–4554.
368. Vogt D, Weber J, Ihlefeld K, Brüggerhoff A, Proschak E, Stark H. Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors. Bioorg Med Chem 2014;22(19):5354–5367.
369. Pitman MR, Powell JA, Coolen C, Moretti, Paul A B, Zebol JR, Pham DH, et al. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget 2015;6(9):7065–7083.
370. Santos WL, Lynch KR. Drugging sphingosine kinases. ACS Chem Biol 2015;10(1):225–233.
371. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat Rev Immunol 2005;5(7):560–570.
372. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007;18(8):300–307.
373. Taha TA, Argraves KM, Obeid LM. Sphingosine-1-phosphate receptors: Receptor specificity versus functional redundancy. Biochim Biophys Acta 2004;1682(1–3):48–55.
374. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115(1):84–105.
375. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009;78:743–768.
376. Aarthi JJ, Darendeliler MA, Pushparaj PN. Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res 2011;90(7):841–854.
377. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, et al. Crystal structure of a lipid G protein-coupled receptor. Science 2012;335(6070):851–855.
378. O'Sullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmacol Sci 2013;34(7):401–412.
379. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54(2):265–269.
380. Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol 2014;171(15):3575–3594.
381. An S, Goetzl EJ, Lee H. Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J Cell Biochem Suppl 1998;30–31:147–157.
382. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000;349(Pt 2):385–402.
383. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010;688:141–155.
384. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8(4):297–307.
385. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8(12):1337–1344.
386. Skoura A, Hla T. Lysophospholipid receptors in vertebrate development, physiology, and pathology. J Lipid Res 2009;50(Suppl):S293–S298.
387. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010;207(13):2793–2798.
388. Ishii M, Kikuta J. Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis. Biochim Biophys Acta 2013;1831(1):223–227.
389. 5 agonists. ChemMedChem 2010;5(10):1693–1696.
390. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol 2010;43(4):394–402.
391. Schulze T, Golfier S, Tabeling C, Räbel K, Gräler MH, Witzenrath M, et al. Sphingosine-1-phospate receptor 4 (S1P₄) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J 2011;25(11):4024–4036.
392. Urbano M, Guerrero M, Velaparthi S, Crisp M, Chase P, Hodder P, et al. Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype. Bioorg Med Chem Lett 2011;21(22):6739–6745.
393. Bolli MH, Lescop C, Nayler O. Synthetic sphingosine 1-phosphate receptor modulators—Opportunities and potential pitfalls. Curr Top Med Chem 2011;11(6):726–757.
394. Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12(9):688–702.
395. Sanllehí P, Abad J, Casas J, Delgado A. Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase). Chem Phys Lipids 2016;197:69–81.
396. Albert R, Hinterding K, Brinkmann V, Guerini D, Müller-Hartwieg C, Knecht H, et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 2005;48(16):5373–5377.
397. Ohno T, Hasegawa C, Nakade S, Kitagawa J, Honda N, Ogawa M. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Biopharm Drug Dispos 2010;31(7):396–406.
398. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012;167(5):1035–1047.
399. Timony G, Brooks J, Powell R, Dedman H, Scott F, Martinborough E, et al. The preclinical safety profile of RPC1063, a selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) agonist. Neurology Neurology 2016;80(7 Suppl):P01.158.
400. Yamamoto R, Okada Y, Hirose J, Koshika T, Kawato Y, Maeda M, et al. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One 2014;9(10):e110819.
401. Cee VJ, Frohn M, Lanman BA, Golden J, Muller K, Neira S, et al. Discovery of AMG 369, a thiazolo[5,4-b]pyridine agonist of S1P 1 and S1P 5. ACS Med Chem Lett 2011;2(2):107–112.
402. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 2008;74(5):1308–1318.
403. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011;337(2):547–556.
404. Xu J, Gray F, Henderson A, Hicks K, Yang J, Thompson P, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev 2014;3(3):170–178.
405. Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005;111(2):222–229.
406. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 2006;13(11):1227–1234.
407. Sanna MG, Liao J, Jo E, Alfonso C, Ahn M, Peterson MS, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004;279(14):13839–13848.
408. Nishi T, Miyazaki S, Takemoto T, Suzuki K, Iio Y, Nakajima K, et al. Discovery of CS-0777: A potent, selective, and orally active S1P1 agonist. ACS Med Chem Lett 2011;2(5):368–372.
409. Nakamura T, Asano M, Sekiguchi Y, Mizuno Y, Tamaki K, Kimura T, et al. Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Bioorg Med Chem Lett 2012;22(4):1788–1792.
410. Cahalan SM, Gonzalez-Cabrera PJ, Sarkisyan G, Nguyen N, Schaeffer M, Huang L, et al. Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Nat Chem Biol 2011;7(5):254–256.
411. Skidmore J, Heer J, Johnson CN, Norton D, Redshaw S, Sweeting J, et al. Optimization of sphingosine-1-phosphate-1 receptor agonists: Effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles. J Med Chem 2014;57(24):10424–10442.
412. Meng Q, Zhao B, Xu Q, Xu X, Deng G, Li C, et al. Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists. Bioorg Med Chem Lett 2012;22(8):2794–2797.
413. Park SW, Kim M, Brown KM, D'Agati VD, Lee HT. Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2012;23(2):266–280.
414. Satsu H, Schaeffer M, Guerrero M, Saldana A, Eberhart C, Hodder P, et al. A sphingosine 1-phosphate receptor 2 selective allosteric agonist. Bioorg Med Chem 2013;21(17):5373–5382.
415. Jo E, Bhhatarai B, Repetto E, Guerrero M, Riley S, Brown SJ, et al. Novel selective allosteric and bitopic ligands for the S1P 3 receptor. ACS Chem Biol 2012;7(12):1975–1983.
416. Guerrero M, Urbano M, Velaparthi S, Zhao J, Schaeffer M, Brown S, et al. Probe development efforts to identify novel agonists of the sphingosine 1-phosphate receptor 4 (S1P4). Probe Reports from the NIH Molecular Libraries Program 2012.
417. Urbano M, Guerrero M, Zhao J, Velaparthi S, Schaeffer M, Brown S, et al. SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P4) receptor. Bioorg Med Chem Lett 2011;21(18):5470–5474.
418. Clemens JJ, Davis MD, Lynch KR, Macdonald TL. Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: Discovery of potent, subtype-selective S1P4 receptor agonists. Bioorg Med Chem Lett 2004;14(19):4903–4906.
419. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, et al. Discovery of A-971432, an orally bioavailable selective sphingosine-1-phosphate receptor 5 (S1P5) agonist for the potential treatment of neurodegenerative disorders. J Med Chem 2015;58(23):9154–9170.
420. Davis MD, Clemens JJ, Macdonald TL, Lynch KR. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 2005;280(11):9833–9841.
421. Wamhoff B, Lynch K, Macdonald T, Owens G. Abstract 1159: Pharmacological inhibition of the sphingosine-1-phosphate receptors type 1 and type 3 with VPC44116 prevents neointimal hyperplasia in the rat carotid artery injury model. Circulation 2006;114(Suppl 18):Abstract1159.
422. Wei SH, Rosen H, Matheu MP, Sanna MG, Wang S, Jo E, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005;6(12):1228–1235.
423. Tarrasón G, Aulí M, Mustafa S, Dolgachev V, Domènech MT, Prats N, et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int Immunopharmacol 2011;11(11):1773–1779.
424. Quancard J, Bollbuck B, Janser P, Angst D, Berst F, Buehlmayer P, et al. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol 2012;19(9):1142–1151.
425. Fujii Y, Ueda Y, Ohtake H, Ono N, Takayama T, Nakazawa K, et al. Blocking S1P interaction with S1P1 receptor by a novel competitive S1P1-selective antagonist inhibits angiogenesis. Biochem Biophys Res Commun 2012;419(4):754–760.
426. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 2002;299(3):483–487.
427. Kusumi K, Shinozaki K, Kanaji T, Kurata H, Naganawa A, Otsuki K, et al. Discovery of novel S1P2 antagonists. Part 1: Discovery of 1,3-bis(aryloxy)benzene derivatives. Bioorg Med Chem Lett 2015;25(7):1479–1482.
428. Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: Investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 2010;77(4):704–713.
429. Oldstone M, Hodder P, Crisp M, Roberts E, Guerrero M, Urbano M, et al. Probe development efforts to identify novel antagonists of the sphingosine 1-phosphate receptor 4 (S1P4). Probe Reports from the NIH Molecular Libraries Program 2010.
430. Cohen JA, Barkhof F, Comi G, Hartung H, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402–415.
431. Kappos L, Radue E, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387–401.
432. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296(5566):346–349.
433. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003;278(48):47408–47415.
434. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003;554(1–2):189–193.
435. Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18(3):551–553.
436. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277(24):21453–21457.
437. van Doorn R, van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010;58(12):1465–1476.
438. Choi JW, Gardell SE, Herr DR, Rivera R, Lee C, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011;108(2):751–756.
439. Cruickshanks N, Roberts JL, Bareford MD, Tavallai M, Poklepovic A, Booth L, et al. Differential regulation of autophagy and cell viability by ceramide species. Cancer Biol Ther 2015;16(5):733–742.
440. White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget 2016;epub ahead of print.
441. Sun WY, Dimasi DP, Pitman MR, Zhuang Y, Heddle R, Pitson SM, et al. Topical application of fingolimod perturbs cutaneous inflammation. J Immunol 2016;196(9):3854–3864.
442. Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol 2013;33(1):37–44.
443. Tanaka M. The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod. Rinsho Shinkeigaku 2016;56(4):270–272.
444. Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 2013;80(2):139–144.
445. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol 2009;53(3):189–197.
446. Imeri F, Blanchard O, Jenni A, Schwalm S, Wünsche C, Zivkovic A, et al. FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P3 and phosphoinositide 3-kinase. Naunyn Schmiedebergs Arch Pharmacol 2015;388(12):1283–1292.
447. Rüger K, Ottenlinger F, Schröder M, Zivkovic A, Stark H, Pfeilschifter JM, et al. Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells. Scand J Immunol 2014;80(6):398–407.
448. Zhang DD, Linke B, Suo J, Zivkovic A, Schreiber Y, Ferreirós N, et al. Antinociceptive effects of FTY720 during trauma-induced neuropathic pain are mediated by spinal S1P receptors. Biol Chem 2015;396(6–7):783–794.
449. Stark H, Zivkovic A, Huwiler A, Pfeilschifter J. Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof. Patent WO 2012 131096 A1, 2012.
450. Selmaj K, Li, DKB, Hartung H, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12(8):756–767.
451. Stuve O, Hartung H, Freedman M, Li D, Hemmer B, Kappos L, et al. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2014;3(6):754–755.
452. Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P 1) and receptor-5 (S1P 5) agonist with autoimmune disease-modifying activity. Br J Pharmacol 2016;173(11):1778–1792.
453. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374(18):1754–1762.
454. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: A randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85(11):1198–1208.
455. Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator P, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;384(9959):2036–2045.
456. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9(3):225–238.
457. O'Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res 2009;50(11):2245–2257.
458. Van Veldhoven PP. Sphingosine-1-phosphate lyase. Meth Enzymol 2000;311:244–254.
459. Fyrst H, Saba JD. Sphingosine-1-phosphate lyase in development and disease: Sphingolipid metabolism takes flight. Biochim Biophys Acta 2008;1781(9):448–458.
460. Bourquin F, Riezman H, Capitani G, Grütter MG. Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure 2010;18(8):1054–1065.
461. Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 2010;50(1):349–362.
462. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, et al. Identification of SR2211: A potent synthetic RORγ-selective modulator. ACS Chem Biol 2012;7(4):672–677.
463. Nakahara K, Ohkuni A, Kitamura T, Abe K, Naganuma T, Ohno Y, et al. The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol Cell 2012;46(4):461–471.
464. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. In: Quinn PJ, Wang X, Eds. Lipids in Health and Disease. Dordrecht, Netherlands: Springer; 2008. p 487–522.
465. Bandhuvula P, Tam YY, Oskouian B, Saba JD. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 2005;280(40):33697–33700.
466. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309(5741):1735–1739.
467. Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem 2009;52(13):3941–3953.
468. Pham THM, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 2010;207(1):17–27.
469. Bagdanoff JT, Donoviel MS, Nouraldeen A, Carlsen M, Jessop TC, Tarver J, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: Discovery of (E)-1-(4-((1R, 2S, 3R)-1,2,3,4-tetrahydroxybutyl)-1 H -imidazol-2-yl)ethanone oxime (LX2931) and (1R, 2S, 3R)-1-(2-(Isoxazol-3-yl)-1 H -imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem 2010;53(24):8650–8662.
470. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012;24(3):335–341.
471. Loh KC, Leong W, Carlson ME, Oskouian B, Kumar A, Fyrst H, et al. Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS One 2012;7(5):e37218.
472. Weiler S, Braendlin N, Beerli C, Bergsdorf C, Schubart A, Srinivas H, et al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J Med Chem 2014;57(12):5074–5084.
473. Cosconati S, Novellino E. The first sphingosine 1-phosphate lyase inhibitors against multiple sclerosis: A successful drug discovery tale. J Med Chem 2014;57(12):5072–5073.
474. Schümann J, Grevot A, Ledieu D, Wolf A, Schubart A, Piaia A, et al. Reduced activity of sphingosine-1-phosphate lyase induces podocyte-related glomerular proteinuria, skin irritation, and platelet activation. Toxicol Pathol 2015;43(5):694–703.
475. Dinges J, Harris CM, Wallace GA, Argiriadi MA, Queeney KL, Perron DC, et al. Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors. Bioorg Med Chem Lett 2016;26(9):2297–2302.
476. Muñoz-Sáez E, de Munck García E, Arahuetes Portero RM, Vicente F, Ortiz-López FJ, Cantizani J, et al. Neuroprotective role of sphingosine-1-phosphate in L-BMAA treated neuroblastoma cells (SH-SY5Y). Neurosci Lett 2015;593:83–89.